Company Overview of Enumeral Biomedical Holdings, Inc.
Enumeral Biomedical Holdings, Inc. engages in discovering and developing antibody immunotherapies that help the immune system fight cancer and other diseases. It is developing antibodies against a number of classes of immunomodulatory proteins expressed on the surface of cells of the immune system for the treatment of cancer, autoimmune, and inflammatory diseases. Enumeral Biomedical Holdings, Inc. has a collaboration agreement with Merck Sharp & Dohme Corp.; and research contract with the National Cancer Institute. Enumeral Biomedical Holdings, Inc. was founded in 2009 and is based in Cambridge, Massachusetts.
200 CambridgePark Drive
Cambridge, MA 02140
Founded in 2009
Key Executives for Enumeral Biomedical Holdings, Inc.
Co-Founder, Chief Executive Officer, President and Director
Total Annual Compensation: $174.6K
Co-Founder and Executive Chairman
Total Annual Compensation: $167.4K
Chief Accounting Officer, Vice President of Finance and Treasurer
Total Annual Compensation: $85.4K
Vice President of Business Development
Total Annual Compensation: $171.3K
Compensation as of Fiscal Year 2014.
Enumeral Biomedical Holdings, Inc. Key Developments
Enumeral Biomedical Holdings, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter Ended June 30, 2015
Aug 12 15
Enumeral Biomedical Holdings, Inc. reported unaudited consolidated earnings results for the second quarter ended June 30, 2015. For the quarter, the company's revenue was $381,313. This increase in revenue is attributable to the Company’s collaboration agreement with Merck and its grant from the National Cancer Institute. Loss from operations was $2,915,870 compared to $1,133,728 a year ago. Net loss before income taxes was $29,019 compared to $1,206,429 a year ago. Net loss was $29,019 compared to $1,206,429 a year ago. Diluted loss per common share was $0.00 compared to $0.06 a year ago. This decrease was primarily due to an increase in the change in fair value of derivative liabilities of $2,878,847 and an increase in revenues of $381,313, offset by an increase of $2,163,455 in research and development and general and administrative expenses.
Enumeral Biomedical Holdings, Inc. Appoints Robert J. Easton to its Board of Directors
Jul 30 15
Enumeral Biomedical Holdings, Inc. announced that it has appointed Robert J. Easton to its Board of Directors. Mr. Easton is a recognized leader in the life sciences and healthcare industries, having led strategy development and supervised opportunity assessments for hundreds of clients across the globe, including large and specialty pharmaceutical companies, early-stage and publicly traded biopharmaceutical companies, and diagnostics businesses. Mr. Easton currently serves as Co-Chairman of Bionest Partners, Inc. Mr. Easton replaces Daniel B. Wolfe, Ph.D., who has stepped down after serving on the Enumeral board since 2009.
Enumeral Biomedical Holdings, Inc. Announces Recent Progress in its PD-1 Antibody Program
Jul 14 15
Enumeral Biomedical Holdings, Inc. announced recent progress in its PD-1 antibody program. Enumeral also provided an update on the progress of additional programs in the company's R&D pipeline, including its TIM-3 antibody program. Enumeral has identified antibodies that appear to bind to PD-1 in a manner different from that of currently marketed anti-PD1 antibodies, while retaining activity in cell-based assays. The company has isolated more than 300 sequences of PD-1 binding antibodies from primary B cells in its PD-1 program. The company's bioinformatics analysis of sequences indicates that these antibodies are diverse, falling into 26 distinct clades, or families, that bind to PD-1. Enumeral has advanced six lead clones into pre-clinical characterization, four of which are undergoing humanization. The company anticipates that the humanization process will be completed by the end of the third quarter of 2015, which will enable initiation of cell line development for IND-enabling studies. In Enumeral's TIM-3 program, the company has isolated 180 screening hits and has sequenced 88 TIM-3 binding antibodies to date, and its screening efforts are ongoing. Enumeral's bioinformatics analysis indicates desirable diversity, with the antibodies falling into 17 unique clades that bind to TIM-3. Enumeral plans to apply its unique approach to cellular immune response profiling to further understand the utility of these different antibodies for modulation of different TILs. The company believes antibodies that block TIM-3 may potentiate anti-cancer immune responses, either as a monotherapy or in combination with other therapies, including other immune checkpoint-targeted drugs. The company currently anticipates nominating lead clones by the end of the third quarter 2015, and beginning the humanization process by the end of this year. Enumeral also noted that it is engaged in ongoing antibody screening in its LAG-3, OX40, and VISTA programs. Using human biopsy samples, the company intends to validate antibody blocking effects against these targets, and then assess potential monotherapy or combination therapy regimens using proprietary antibodies.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|